Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
HUTCHMED sold the rights to one of its cancer medicines to a much bigger company (GSK) for $1.3 billion, which is great money for them. When a company gets a big cash boost like this, it's a sign other big companies think their work is valuable—something to notice about the company's future strength.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.